TP53 and acute myeloid leukemia: This indicates that Csnk1a1 is a treatment target in acute myeloid leukaemia. It was found that knocking out Csnk1a1 reduces Rps6 phosphorylation in AML cells, induces p53 expression and inhibits tumour cell proliferation.